Bio-Rad Laboratories (BIO.B) versus Precipio (NASDAQ:PRPO) Head to Head Contrast

Bio-Rad Laboratories (NYSE:BIO.B) and Precipio (NASDAQ:PRPO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Earnings & Valuation

This table compares Bio-Rad Laboratories and Precipio’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Rad Laboratories $2.29 billion 3.93 $365.61 million N/A N/A
Precipio $2.86 million 13.92 -$15.69 million N/A N/A

Bio-Rad Laboratories has higher revenue and earnings than Precipio.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Bio-Rad Laboratories and Precipio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories 0 0 0 0 N/A
Precipio 0 0 0 0 N/A

Profitability

This table compares Bio-Rad Laboratories and Precipio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories 24.84% 4.15% 2.99%
Precipio -546.92% -141.30% -58.82%

Insider & Institutional Ownership

0.1% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 10.0% of Precipio shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 9.2% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Bio-Rad Laboratories has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Precipio has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Summary

Bio-Rad Laboratories beats Precipio on 6 of the 9 factors compared between the two stocks.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

About Precipio

Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer. The company is based in New Haven, Connecticut.

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.